Saurabh Saha bought $254K of Clarivate (CLVT)
Executed Mar 3 2025, disclosed Mar 5 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 5 2025), the stock returned -3.4% (delay-adjusted); from the execution session (Mar 3 2025), -8.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
Saurabh Saha (Director) filed 13 Form 4 reports in the past 24 months (1 purchase, 12 sales), most often in Centessa Pharmaceuticals plc (CNTA). Across 1 priced purchase filing, the average 21-session return was -8.8% from execution and -3.4% from disclosure (delay-adjusted; derived). The largest single filing was $1.6M of CNTA (87,496 sh × $18.46, as filed), executed Dec 6 2024.
Technology · Clarivate Plc provides information services in the Americas, the Middle East, Africa, Europe, and the Asia Pacific
More Technology filings→ Insider filings, newest first→ View the original filing at www.sec.gov→